AB472-1mg / 询价
- 关联产品
- 客服电话
- 技术支持
Anti-PCSK9 Antibody (Alirocumab Biosimilar)
Human/Cynomolgus
PCSK9
Human IgG1-Kappa
Unconjugated
protein A
0.2 μM filtered
PBS, 10% glycerol (pH 7.4)
Less than 1 EU per μg by the LAL method.
（Recommended Dilution Buffer）
PBS (pH 7.4), contains no stabilizers or preservatives.
<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>
<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>
ELISA
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
(1)McKenney, James M. Understanding PCSK9 and anti-PCSK9 therapies[J]. Journal of Clinical Lipidology, 2015, 9(2):170-186.
